Altimmune, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Altimmune appointed Peter Greenleaf (former CEO of Aurinia, Sucampo, Cerecor) and Alex Howarth (former CFO of Madrigal, COO at Akcea) to the board effective November 2, 2026. Three incumbent directors—John M. Gill, Mitchel Sayare, and Klaus O. Schafer—will retire at the 2027 Annual Meeting. The appointments reflect the company's transition to late-stage clinical development as pemvidutide (dual glucagon/GLP-1 agonist for liver disease) advances through Phase 3 MASH and Phase 2 AUD trials.
Why this rating
Board refresh with proven biotech operators signals strategic credibility and commercialization readiness; routine for stage transition but adds expertise. Immaterial to $327M market cap.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.